Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'

Thread starter International: Top News And Analysis
Start date Mar 28, 2025

International: Top News And Analysis

Guest

Mar 28, 2025

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

Continue reading...

You must log in or register to reply here.

Facebook X Bluesky LinkedIn Reddit Pinterest Tumblr WhatsApp Email Link

Thread Information

Title: Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'

Prefix: N/A

Forum: World News

Start date: Mar 28, 2025

Last reply date: Mar 28, 2025

Replies: 0

Thread Tags

Thread statistics

Created: International: Top News And Analysis, Mar 28, 2025

Replies: 0

Views: 26

About Us

XenTR Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Color picker

Search